Avid Technology Announces Amendment to Financing Agreement

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
124
Avid Technology Announces Amendment to Financing Agreement

BURLINGTON, Mass., March 20, 2017 (GLOBE NEWSWIRE) -- Avid® ( Nasdaq: AVID ), a leading technology provider for the creation, distribution and monetization of media assets for global media organizations, enterprise users and individual creative professionals, today announced an amendment to its existing financing agreement with Cerberus Business Finance, LLC, originally entered into on February 26, 2016.

More Favorable Leverage Ratios The company and Cerberus agreed to more favorable leverage ratio requirements for future periods, beginning the quarter ending June 30, 2017 and extending to the final year of the agreement. The updated schedule of leverage ratios more accurately reflects the impact related to the elimination of implied post contract support (“PCS”) revenue. The table below summarizes the changes to the leverage ratios for each quarter in 2017:

  2017 Quarter Ending:
March 31 June 30 September 30 December 31
Original Ratio 3.50 3.50 3.50 3.30
Amended Ratio 3.50 4.20 4.75 4.80
Favorable Ratio Change No change 0.70 1.25 1.50

Commitment to Efficiency Program The company and Cerberus agreed to expand the aggregate amount of allowable one-time charges incurred after February 26, 2016, including restructuring activities and other non-recurring costs, from $28.1 million to $38.0 million. During 2016, Avid successfully executed an efficiency program that reduced its operating cost structure. The increased limit on one-time charges will provide the company with additional covenant cushion as it executes on further planned efficiencies, including greater than $30 million of cost savings in 2017, leading to a leaner and more directed cost structure as Avid completes its transformation. 

Use of Equity Proceeds The agreement acknowledged that proceeds from potential equity sale transactions, including the common stock equity offering expected to close with Beijing Jetsen Technology Co., Ltd. by the end of Q2 2017, may be retained on the balance sheet in the form of cash. Avid will have flexibility to manage its balance sheet with improved liquidity as it capitalizes on opportunities that position the business for future growth.

"We are pleased to have worked with our lender, Cerberus, on this amendment to our financing agreement,” said Brian E. Agle, Avid’s Senior Vice President and Chief Financial Officer. “As our financing partner, Cerberus responded to our request and demonstrated its support for Avid as we complete the transformation and deliver a clearer, more predictable and profitable financial model.”

Forward-Looking Statements The information provided in this press release includes forward-looking statements that involve risks and uncertainties. Such statements are made in reliance upon the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements, which are based on certain assumptions and describe Avid’s future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. All statements in this release that are not based on historical fact are "forward-looking statements." Forward-looking statements include but are not limited to: the planned equity investment by Jetsen; the completion of our transformation; and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations as of the date of this release and subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to the risk that the investment of Jetsen in Avid may not receive regulatory approval or may not close for other reasons; and the risk that we may not complete our transformation timely, or at all. The risks included above are not exhaustive. Other factors that could adversely affect Avid’s business and prospects are described in the filings made by Avid with the SEC. Avid expressly disclaims any obligation or undertaking to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

About Avid Through  Avid Everywhere™ , Avid delivers the most open and efficient media platform, connecting content creation with collaboration, asset protection, distribution and consumption. Avid’s preeminent customer community uses Avid’s comprehensive tools and workflow solutions to create, distribute and monetize the most watched, loved and listened to media in the world—from prestigious and award-winning feature films, to popular television shows, news programs and televised sporting events, and celebrated music recordings and live concerts. With the most flexible deployment and pricing options, Avid’s industry-leading solutions include Pro Tools®, Media Composer®, Avid NEXIS™, Interplay®, ProSet™ and RealSet™, Maestro™, PlayMaker™, and Sibelius®. For more information about Avid solutions and services, visit  www.avid.com , connect with Avid on  Facebook ,  Instagram , Twitter , YouTube ,  LinkedIn , or subscribe to  Avid Blogs .

© 2017 Avid Technology, Inc. All rights reserved. Avid, the Avid logo, Avid Everywhere, Avid NEXIS, iNEWS, Interplay, AirSpeed, MediaCentral, Media Composer, PhaseFind, Pro Tools, ScriptSync and Sibelius are trademarks or registered trademarks of Avid Technology, Inc. or its subsidiaries in the United States and/or other countries. The Interplay name is used with the permission of the Interplay Entertainment Corp. which bears no responsibility for Avid products. Product features, specifications, system requirements and availability are subject to change without notice.

 

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action Suit: Key Deadlines Loom

Updated Category News Views 188

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 296

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Amplifon Data Breach Spurs Legal Scrutiny for Millions

Updated Category News Views 319

Data Breach Fallout: Amplifon Under Fire When a big player like Amplifon gets hit with a data breach, it's like a wake-up call across the board. This one’s no small spill—over 1.3 million folks left wondering whether their personal information is fluttering around cyberspace for all who dare to peek. If you’ve missed the memo, Edelson Lechtzin LLP, the savvy cats in...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 240

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 283

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 462

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
TCL's Display Future: AI Meets Screens at DTC 2026

Updated Category News Views 597

Exploring New Horizons in Display Technology There's something brewing in Wuhan: a conference that’s shaping up like a tech enthusiast’s dream. This year, it's all about the symbiosis of cutting-edge tech and dazzling visuals as TCL CSOT gears up to unveil advancements at the Global Display Tech-Ecosystem Conference (DTC) 2026. If you're wondering whether this event...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 81

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 246

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading

Top 5 Most Recently Viewed Articles

New Partnership Expands Eco-Friendly Solutions in the South

Updated Category News Views 234

Expanding Environmental Solutions in the Southern States Easy Environmental Solutions Inc., formerly known as Digital Utilities Ventures, is excited to announce a significant partnership with Organic Living Soil, LLC. As the exclusive dealer for Easy Environmental Solutions in Louisiana and Mississippi, Organic Living Soil aims to revolutionize the way eco-friendly...

Continue Reading
Michael Young Enhances Ty J. Young Wealth Management Team

Updated Category News Views 244

Michael Young Joins Ty J. Young Wealth Management Ty J. Young Wealth Management, a prominent name in financial services, proudly announces the appointment of Michael Young as Vice President of Business Development. With a wealth of experience from his previous role as a sales executive in a Fortune 500 company, Young is set to take the lead in expanding the firm's...

Continue Reading
Johnson & Johnson Advances Myeloma Treatment with FDA Application

Updated Category News Views 289

Johnson & Johnson took a big swing back in 2024 when they submitted a supplemental Biologics License Application (sBLA) for their myeloma treatment, DARZALEX FASPRO®. This move aimed at getting the green light from the FDA for use among newly diagnosed multiple myeloma patients who couldn't go through autologous stem cell transplants. Desks buzzed with chatter on how...

Continue Reading
What Investors Should Anticipate in ScanSource's Earnings Report

Updated Category News Views 121

ScanSource's Earnings Report: Expectations and Insights ScanSource (NASDAQ:SCSC) is gearing up to release its quarterly earnings report soon. Investors are particularly interested in the results that are expected to be announced shortly. With the anticipation building, understanding what to look for is essential. Predicted Earnings Results Industry experts have estimated...

Continue Reading
Revealing the Truth: IRS Data Access by Immigration Authorities

Updated Category News Views 127

IRS Data Accessed by Immigration Authorities: An Overview Federal immigration officials gained access to taxpayer information from the IRS during the previous administration's deportation efforts, though they claim this data was not used to identify individuals for removal. This raises serious questions surrounding privacy and immigration enforcement. Cross-Referencing...

Continue Reading